Company profile: Oragenics
1.1 - Company Overview
Company description
- Provider of development-stage therapeutics and vaccines, including lantibiotics targeting antibiotic-resistant, healthcare-acquired infections; neurosteroids ONP-002 for moderate to severe concussion and ONP-001 for Niemann Pick Type-C disease; and NT-CoV-2, an intranasal COVID-19 vaccine candidate designed to enhance mucosal immunity and reduce needle use.
Products and services
- Lantibiotics: Development-stage class of antimicrobial agents effective against antibiotic-resistant bacteria, particularly those causing healthcare-acquired infections, engineered to address critical infectious disease needs
- NT-CoV-2: Intranasal-delivered vaccine candidate architected to prevent COVID-19 and its variants by enhancing mucosal immunity and reducing the need for needles during administration
- ONP-002: Preclinical-stage neurosteroid developed for moderate to severe concussion, showing positive preclinical effects and a good safety profile in animal studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oragenics
Mazza Innovation
HQ: Canada
Website
- Description: Provider of water-based, solvent-free extraction technology and services to isolate bioactive phytochemicals, including polyphenols, from plants for foods, pharmaceuticals and cosmetics. Offers pressurized low polarity water (PLPW) PhytoClean Method, a manufacturing facility for bioactive extracts, product development from bench to full-scale including biomass sourcing, toll-processing, research and analysis, and custom extraction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mazza Innovation company profile →
Filament Biosolutions
HQ: United States
Website
- Description: Provider of medical foods and functional foods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Filament Biosolutions company profile →
Yves Ponroy
HQ: France
Website
- Description: Provider of an online store offering a variety of supplements, infusions, cosmetics, essential oils, wellness, and beauty products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Yves Ponroy company profile →
Invivo Healthcare
HQ: United Kingdom
Website
- Description: Provider of therapeutic formulas and laboratory diagnostics for healthcare practitioners and their patients, including EcologiX microbiome testing with immune and inflammatory markers, Urinary EcologiX for the female urinary microbiome (15 key bacteria), and Bio.Me probiotics such as IB+ (E. faecium, B. subtilis) and Mind + Mood (live bacteria and biotin) to support gut and psychological function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Invivo Healthcare company profile →
Nuritas
HQ: Ireland
Website
- Description: Provider of AI- and genomics-driven discovery of natural bioactive peptides and scientifically proven active ingredients to manage and improve human health; products include PeptiStrong (increases muscle protein synthesis, reduces breakdown, lowers exercise-induced inflammation), PeptiNourish (maintains muscle, supports vitality), PeptiTone (supports muscle tone and recovery), PeptiControl (targets glucose uptake and fullness), and PeptiSleep (improves sleep quality, focus, reduces morning grogginess).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuritas company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oragenics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oragenics
2.2 - Growth funds investing in similar companies to Oragenics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oragenics
4.2 - Public trading comparable groups for Oragenics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →